Table 1.
Clinical features of AITD patients from PBMC samples
| PBMCs | HT | GD | Controls |
|---|---|---|---|
| N | 12 | 15 | 13 |
| Gender (F/M) | 11/1 | 12/3 | 9/4 |
| Age, yrears | 39 (28-50) | 50 (35-59) | 31 (27-34) |
| Ophthalmopathy | 0 | 3 | 0 |
| TSH, mU/mL | 9.12 (6.93-16.85) | 0 | 1.95 (1.76-3.11) |
| T4, ng/dL | 1.02 (0.73-1.17) | 2.81 (2.47-3.73) | 1.12 (1.09-1.25) |
| Tg-Ab, UI/mL | 403 (20-1475.25) | 20 (20-505.25) | 20 (20-20) |
| TPO-Ab, UI/mL | 697.5 (338.75-1264.25) | 144.5 (20-417.5) | 20 (20-20) |
| TSHR-Ab, U/L | 1 (0.56-1.5) | 4.44 (2.48-11.85) | - |
Values show number for categorical values and median (interquartile intervals 25%-75%) for continuous variables.
Abbreviations: F/M = female/male; T4, thyroxine (normal range = 0.93-1.7); Tg-Ab, anti-thyroglobulin antibody (negative < 344); TPO-Ab, anti-thyroid peroxidase antibody (negative < 100); TSH, thyrotropin (normal range = 0.27-4.20); TSHR-Ab, anti-thyrotropin receptor antibody (negative < 0.7).